Edition:
United Kingdom

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

4.74EUR
22 Aug 2018
Change (% chg)

€-0.01 (-0.29%)
Prev Close
€4.75
Open
€4.73
Day's High
€4.74
Day's Low
€4.72
Volume
591
Avg. Vol
145,702
52-wk High
€11.40
52-wk Low
€4.33

Latest Key Developments (Source: Significant Developments)

Innate Pharma Announces Promising Anti-Tumor Activity Of Monalizumab With Cetuximab In SCCHN
Tuesday, 17 Apr 2018 

April 17 (Reuters) - INNATE PHARMA SA ::PROMISING ANTI-TUMOR ACTIVITY OF MONALIZUMAB WITH CETUXIMAB IN SCCHN.8 PARTIAL RESPONSES IN 26 PATIENTS EVALUABLE FOR EFFICACY IN MONALIZUMAB PHASE I/II TRIAL.NUMBER OF RESPONSES NEEDED TO DECLARE TRIAL RESULT POSITIVE IS REACHED.COMBINATION WAS WELL TOLERATED, WITHOUT POTENTIATING CETUXIMAB-RELATED SIDE EFFECTS.TOTAL ENROLLMENT OF 40 PATIENTS NOW COMPLETED.  Full Article

Innate Pharma Appoints Jean-Yves Blay To Its Supervisory Board
Wednesday, 31 Jan 2018 

Jan 31 (Reuters) - INNATE PHARMA SA ::INNATE PHARMA SA - JEAN-YVES BLAY APPOINTED TO INNATE PHARMA SUPERVISORY BOARD.  Full Article

Eric Vivier Joins Innate Pharma As Chief Scientific Officer
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Innate Pharma Sa ::REG-WORLD RENOWNED IMMUNOLOGIST, PROFESSOR ERIC VIVIER, JOINS INNATE PHARMA AS CHIEF SCIENTIFIC OFFICER.  Full Article

Innate Pharma provides an update on lirilumab
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - INNATE PHARMA SA ::REG-INNATE PHARMA PROVIDES AN UPDATE ON LIRILUMAB.‍LIRILUMAB CONTINUES TO BE WELL-TOLERATED IN MONOTHERAPY AND IN COMBINATION ACROSS MULTIPLE TUMOR INDICATIONS.COMBINATION OF NIVOLUMAB PLUS LIRILUMAB IN EXTENDED POPULATION OF PATIENTS WITH SCCHN DID NOT PROVIDE CLEAR EVIDENCE OF BENEFIT TO PATIENTS OR OBVIOUS DEVELOPMENT PATH.‍‍ON COMBINATION OF NIVOLUMAB PLUS LIRILUMAB: DISCUSSIONS ARE ONGOING REGARDING NEXT STEPS.AN UPDATE IS PLANNED FOR EARLY 2018​.  Full Article

Innate Pharma Q3 revenue up at 12.4 million euros
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - INNATE PHARMA SA ::Q3 REVENUE EUR 12.4 MILLION VERSUS EUR 11.2 MILLION YEAR AGO.9 MONTH REVENUE EUR 27.9 MILLION VERSUS EUR 27.9 MILLION YEAR AGO.CASH POSITION AT SEPT 30 EUR 195.7 MILLION VERSUS EUR 239.6 MILLION YEAR AGO.  Full Article

Innate Pharma H1 operating loss widens to 18.2 million euros
Monday, 18 Sep 2017 

Sept 18 (Reuters) - INNATE PHARMA SA ::‍CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS(1) FOR COMPANY AMOUNTED TO EUR 204.1M (MILLION EUROS) AS OF JUNE 30, 2017​.‍A NET LOSS FOR FIRST HALF OF 2017 AMOUNTING TO EUR 23.4M (EUR 3.2M FOR FIRST HALF OF 2016).​.H1 REVENUE EUR 21.3 MILLION VERSUS EUR 20.7 MILLION YEAR AGO.H1 OPERATING LOSS EUR 18.2 MILLION VERSUS LOSS OF EUR 2.9 MILLION YEAR AGO.  Full Article

  • Previous
  • Next

Innate Pharma SA News

French and Benelux stocks-Factors to watch on April 18

April 18 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

» More IPH.PA News

Earnings vs. Estimates

» More Financials